New Omicron variant line circulating in Peru — MercoPress


New Omicron variant lineage circulating in Peru

Saturday May 7, 2022 – 10:18 UTC

The new line BA.1.22 is a product of the natural evolution of the virus in the Peruvian population

Peru’s Ministry of Health officials announced this week the discovery of a new lineage of the SARS.CoV-2 Omicron variant called BA.1.22.

“The new BA.1.22 lineage is a product of the natural evolution of the virus in the Peruvian population and has been identified mainly in the Tacna region, but cases have already been detected in Loreto, Arequipa, Moquegua, Puno and Lima” , the ministry said in a statement.

The genomic surveillance team of the National Institute of Health (INS) detected this new line which does not present new or different mutations from those previously (or previously recorded) in Omicron.

With this discovery, there are now ten lines that have been identified and proposed by the Genomic Surveillance Laboratory of the National Institute of Health of Peru (INS) for registration and which have been accepted by the international PANGO committee in the United Kingdom. United.

“Genomic surveillance is used to make public health decisions and strengthen control of the epidemic in the face of the emergence of new mutants of the SARS-CoV-2 virus on the national territory”, declared the head of the INS , Carlos Padilla.

The INS also pointed out that, since the entry of the Omicron variant in Peru in December, genomic sequencing has made it possible to observe the new modifications or mutations that this variant has undergone due to the multiple infections recorded.

The Ministry of Health indicated in its latest information that 240 cases of COVID-19 have been registered and 5 people have died from this disease. Peru has 16.2 million people vaccinated with all three doses, representing 56.9% of its population.

Also on vaccines, the Food and Drug Administration (FDA) has restricted the use of Johnson & Johnson’s single-dose vaccine due to the risk of rare blood clots. The FDA said in a statement that emergency authorization for the J&J drug will now be limited to people 18 and older for whom other vaccines are not available or medically appropriate, or who do not wish to receive another. vaccine.

The change is due to the risk of developing a rare and dangerous type of clot, called thrombosis with thrombocytopenia syndrome (TTTS), after receiving the vaccine, it has been reported.

“We are closely monitoring the vaccine and the occurrence of TTTS after inoculation and using updated information from our security services to review emergency clearance,” said Dr. Peter Marks, director of the center of FDA Biologics Evaluation and Research.

According to official data, approximately 18 million doses of the J&J vaccine have been administered in the United States, or approximately 7.7% of citizens considered fully vaccinated in the country. The FDA, however, noted the rarity of this dangerous condition, with 3.23 cases per million doses of vaccine administered and nine confirmed deaths.


Comments are closed.